VRx 510
Alternative Names: SNS 510; VRx-510Latest Information Update: 28 May 2025
At a glance
- Originator Biogen; Sunesis Pharmaceuticals
- Developer Sunesis Pharmaceuticals; Viracta Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action 3-phosphoinositide-dependent protein kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Sarcoma; Solid tumours
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Sarcoma in USA (PO)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (PO)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)